Published Research
September 29, 2022
Accelerating therapeutic discoveries for heart failure: a new public–private partnership
The Accelerating Medicines Partnership in Heart Failure is designed to deliver tools and knowledge that enable the development of new approaches to treat heart failure with preserved ejection fraction, which is considered the largest unmet need in cardiovascular medicine.
Nature Reviews Drug Discovery 21, 781-782 (2022)
doi: https://doi.org/10.1038/d41573-022-00158-3
August 21, 2022
The Future of HFpEF Research
Drs. Sanjiv Shah (overall for PI HeartShare DTC) and Frank Heinzel have outlined the future of heart failure with preserved ejection fraction (HFpEF) in a recently published article in Herz, titled “The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics.” This article explores many topics the AMP Heart Failure program seeks to address.
Here we provide a framework for understanding the phenotype-based approach to HFpEF by reviewing (1) the historical context of HFpEF; (2) the current HFpEF paradigm of comorbidity-induced inflammation and endothelial dysfunction; (3) various methods of sub-phenotyping HFpEF; (4) comorbidity-based classification and treatment of HFpEF; (5) machine learning approaches to classifying HFpEF; (6) examples from HFpEF clinical trials; and (7) the future of phenomapping (machine learning and other advanced analytics) for the classification of HFpEF.
Heinzel, F.R., Shah, S.J. The future of heart failure with preserved ejection fraction. Herz 47, 308–323 (2022). https://doi.org/10.1007/s00059-022-05124-8